APVO

Insider Trades

Name	Value	Action	Price	Current Price
Grant Grady IIIDirector $20k13.5k shares BuyNov 10, 2025 $1.49 --

News

accessnewswire.comAptevo Therapeutics Appoints Mary J. Janatpour, Ph.D.accessnewswire.comMay 28

accessnewswire.comAptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closingaccessnewswire.comMay 27

zacks.comAll You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buyzacks.comMay 20

accessnewswire.comAptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selectionaccessnewswire.comMay 13

accessnewswire.comAptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selectionaccessnewswire.comMay 6

Trade APVO

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.

CEO: Jeffrey G. Lamothe
IPO Date: Jul 20, 2016

Market Data

Open: $4.81
High: $4.84
Low: $4.67
Volume: 16.5K
Avg Volume: 38.3K
52W High: $70.65
52W Low: $3.80

Valuation

Market Cap: $10M
Enterprise Value: $110k
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-26M
Revenue: $0
Net Income: $-26M
Cash: $22M
Debt: $4.6M

Events

EarningsAug 10

EPS est. -6.02